From:  Transcriptional modulation of the PI3K/AKT/mTOR signaling pathway mediated by HPV16 E5, E6, and E7 oncogene expression in breast cancer

 Characterization of the samples regarding patient age, tumor type, and expression of HPV16 oncogenes in the samples.

Clinical and histopathological characteristicsHPV16-positiveHPV16-negativeORIC50p-value
Age1.439p global (0.7714)
30–50 (ref)1021.00
51–701770.4860.084–2.8090.4199
> 70820.8000.091–7.0020.8402
Not-identified201.1900.042–33.4270.9184
Total3711
Molecular typep global (0.6296)
HER-2110.2350.012–4.6240.3410
Luminal A (ref)1741.00
Luminal B1340.7650.16–3.6490.7365
Triple-negative301.8000.078–41.550.7136
Not-identified320.3530.043–2.8670.3298
Total3711
Histological typep global (0.268)
Ductal in situ511.1110.109–11.3310.9291
Invasive ductal (ref)2761.00
Lobular in situ00
Invasive lobular00
Other types120.1110.009–1.4350.0923
Not-identified420.4440.066–3.0140.4063
Total3711

The ages of the patients ranged from 30–50 years, 51–70 years, and over 70 years. Regarding HPV16 status, patients were classified as HPV16-positive or HPV16-negative. Concerning tumor subtype, patients were categorized as luminal A, luminal B, HER2-positive, or triple-negative. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between clinicopathological variables and HPV16 status. The reference categories were: age (30–50 years), molecular subtype (luminal A), and histological type (invasive ductal carcinoma).